Chemomab Therapeutics Ltd. Increase Decrease Through Loss Of Control Of Subsidiary Deferred Tax Liability Asset
Chemomab Therapeutics Ltd. (CMMB) reported Increase Decrease Through Loss Of Control Of Subsidiary Deferred Tax Liability Asset of $132.00 thousand for the 12-month period ending 2018-12-31, per its 20-F filed 2019-04-24.
Discontinued › Notes › Income Taxes
ifrs-full:IncreaseDecreaseThroughLossOfControlOfSubsidiaryDeferredTaxLiabilityAsset · last filed 2019-04-24
| Period end | Increase Decrease Through Loss Of Control Of Subsidiary Deferred Tax Liability Asset 12 month |
|---|---|
| 2018-12-31 | $132.00K 20-F · filed 2019-04-24 |
| 2017-12-31 | $129.00K 20-F · filed 2019-04-24 |
| 2016-12-31 | $52.00K 20-F · filed 2019-04-24 |